Eli Lilly (LLY) USD (CDI)
Sell:$884.12Buy:$884.67
$24.81
(2.89%)
- This stock can be held in a
Stocks and Shares ISA$24.81
(2.89%)$24.81
(2.89%)Company Information
About this company
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity, and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It also owns a lead therapeutic molecule, FXR314.
Key people
Key facts
- EPICLLY
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS5324571083
- Market cap$786.28bn
- Employees47,000
- Shares in issue948.35m
- ExchangeNew York Stock Exchange
- IndexS&P 500, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.